Category: Automation and High-Throughput Technologies
The latest market reports state that the global biologics market will expand to US$480 million by 2024, with the segment of monoclonal antibodies representing an annual share of 43% in 2016 and a CAGR of 11.9% from 2016 through 2024*.
Biologics are an important class of targets in drug discovery that are proven to be effective therapeutics and comprise a variety of products from monoclonal antibodies to vaccines. Their characterization and the associated workflows from early discovery to formulation and final FDA approval can often be very complex, time- and –money consuming and often lack the accuracy and precision needed to appropriately monitor and characterize drug candidates. In this poster, we show the use of a single platform for long-term stability prediction of biologics using a combination of thermal and chemical unfolding analysis. Specifically, we were able to monitor the stability of different mAb formulations and establish their degree of aggregation and show that this type of protein characterization can be done at any stage of the workflow, from assay development to processing and QC. In addition, the high throughput and automation of this platform offers robust, efficient and accurate analysis and characterization of biologics workflow.
*Transparency Market Research, January 2018.
Patricia Piatti– Product Marketing Manager, Nanotemper Technologies, Inc, South San Francisco, CA